|
G |
Alb |
albumin |
affects binding |
ISO |
chromotrope 2R binds to ALB protein |
CTD |
PMID:19347248 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
multiple interactions |
ISO |
Benzenesulfonates analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:22641618 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions affects binding |
ISO |
Congo Red inhibits the reaction [APP protein binds to APP protein] Congo Red binds to APP protein |
CTD |
PMID:17323972 PMID:17406451 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Prnp |
prion protein |
decreases expression |
EXP |
Congo Red results in decreased expression of PRNP protein alternative form |
CTD |
PMID:11994310 |
|
NCBI chr 2:131,751,848...131,780,356
Ensembl chr 2:131,751,848...131,780,349
|
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Fast Green FCF inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr10:3,490,274...3,504,880
Ensembl chr10:3,490,240...3,504,877
|
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions affects binding |
ISO EXP |
Indigo Carmine binds to and results in increased activity of AHR protein Indigo Carmine binds to AHR protein |
CTD |
PMID:11425848 PMID:15001395 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Chrna4 |
cholinergic receptor, nicotinic, alpha polypeptide 4 |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein |
CTD |
PMID:23429044 |
|
NCBI chr 2:180,664,104...180,685,339
Ensembl chr 2:180,660,173...180,685,339
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of CHRNB2 protein |
CTD |
PMID:23429044 |
|
NCBI chr 3:89,660,755...89,671,939
Ensembl chr 3:89,653,502...89,671,939
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions |
ISO EXP |
Indigo Carmine results in increased activity of CYP1A1 protein Indigo Carmine results in increased expression of CYP1A1 mRNA Indigo Carmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:15001395 PMID:15882963 PMID:18493746 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Grin2a |
glutamate receptor, ionotropic, NMDA2A (epsilon 1) |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of GRIN2A protein; [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of GRIN2A protein |
CTD |
PMID:23429044 |
|
NCBI chr16:9,385,765...9,813,744
Ensembl chr16:9,385,762...9,813,424
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions decreases activity |
ISO |
Indocyanine Green inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Indocyanine Green results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
affects export |
EXP |
ABCB4 protein affects the export of Indocyanine Green |
CTD |
PMID:11302927 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Bax |
BCL2-associated X protein |
increases expression |
ISO |
Indocyanine Green results in increased expression of BAX mRNA; Indocyanine Green results in increased expression of BAX protein |
CTD |
PMID:23675521 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
Indocyanine Green results in increased expression of CASP9 mRNA; Indocyanine Green results in increased expression of CASP9 protein |
CTD |
PMID:23675521 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
multiple interactions increases uptake |
ISO |
Nifedipine promotes the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green] |
CTD |
PMID:32209977 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slc10a2 |
solute carrier family 10, member 2 |
increases uptake |
ISO |
SLC10A2 protein results in increased uptake of Indocyanine Green |
CTD |
PMID:32209977 |
|
NCBI chr 8:5,133,219...5,155,287
Ensembl chr 8:5,133,219...5,155,351
|
|
G |
Slc16a2 |
solute carrier family 16 (monocarboxylic acid transporters), member 2 |
multiple interactions |
ISO |
Indocyanine Green inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine] |
CTD |
PMID:28119167 |
|
NCBI chr X:102,741,020...102,865,594
Ensembl chr X:102,741,020...102,865,589
|
|
G |
Slc22a7 |
solute carrier family 22 (organic anion transporter), member 7 |
multiple interactions |
EXP |
Indocyanine Green inhibits the reaction [SLC22A7 protein results in increased uptake of Glutarates] |
CTD |
PMID:12065749 |
|
NCBI chr17:46,743,111...46,749,403
Ensembl chr17:46,743,109...46,749,383
|
|
G |
Slc22a8 |
solute carrier family 22 (organic anion transporter), member 8 |
multiple interactions |
ISO |
Indocyanine Green inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:10224140 |
|
NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions increases uptake increases transport |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [ABCG2 protein results in increased uptake of lucifer yellow]; Novobiocin inhibits the reaction [ABCG2 protein results in increased uptake of lucifer yellow]; Omeprazole inhibits the reaction [ABCG2 protein results in increased transport of lucifer yellow] |
CTD |
PMID:31348918 PMID:32305507 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO |
Dipyrone inhibits the reaction [IL1B protein results in increased secretion of CRH protein]; Dipyrone inhibits the reaction [IL6 protein results in increased secretion of CRH protein]; Dipyrone inhibits the reaction [Lipopolysaccharides results in increased secretion of CRH protein]; Dipyrone inhibits the reaction [TNF protein results in increased secretion of CRH protein] |
CTD |
PMID:11852909 |
|
NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein] |
CTD |
PMID:15309881 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Dipyrone inhibits the reaction [IL1B protein results in increased secretion of CRH protein] |
CTD |
PMID:11852909 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Dipyrone inhibits the reaction [IL6 protein results in increased secretion of CRH protein] |
CTD |
PMID:11852909 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
ISO EXP |
Dipyrone analog results in decreased activity of PTGS1 protein; Dipyrone results in decreased activity of PTGS1 protein |
CTD |
PMID:12242329 PMID:16141368 |
|
NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein] |
CTD |
PMID:15309881 |
|
NCBI chr 6:86,172,020...86,252,726
Ensembl chr 6:86,172,205...86,252,701
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Dipyrone inhibits the reaction [TNF protein results in increased secretion of CRH protein] |
CTD |
PMID:11852909 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Direct Red 81 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr10:3,490,274...3,504,880
Ensembl chr10:3,490,240...3,504,877
|
|
|
G |
Il17a |
interleukin 17A |
increases expression |
ISO |
Sodium taurocholate increases expression of Il17a mRNA and protein in the pancreas |
RGD |
PMID:22990529 |
RGD:9068935 |
NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:95,701,321...95,740,836
Ensembl chr 8:95,701,379...95,740,845
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:138,121,217...138,138,444
Ensembl chr 3:138,121,227...138,136,653
|
|
G |
Adh6b |
alcohol dehydrogenase 6B (class V) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:138,047,176...138,064,621
Ensembl chr 3:138,047,536...138,064,622
|
|
G |
Akr1c6 |
aldo-keto reductase family 1, member C6 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1C4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:4,484,354...4,507,529
Ensembl chr13:4,484,305...4,507,876
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:37,506,913...37,551,856
Ensembl chr 6:37,507,108...37,545,750
|
|
G |
Akr7a5 |
aldo-keto reductase family 7, member A5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:110,367,291...110,411,612
Ensembl chr 7:110,367,413...110,411,612
|
|
G |
Apoa1 |
apolipoprotein A-I |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Atp8b1 |
ATPase, class I, type 8B, member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:64,662,050...64,794,342
Ensembl chr18:64,662,038...64,794,338
|
|
G |
Baat |
bile acid-Coenzyme A: amino acid N-acyltransferase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:49,489,416...49,507,915
Ensembl chr 4:49,489,422...49,506,557
|
|
G |
Bach1 |
BTB and CNC homology 1, basic leucine zipper transcription factor 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:87,495,842...87,530,234
Ensembl chr16:87,495,833...87,530,234
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Tartrazine co-treated with Erythrosine] affects the expression of CASP9 mRNA |
CTD |
PMID:32981412 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
ISO |
Tartrazine results in decreased activity of CAT protein [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA |
CTD |
PMID:20678534 PMID:33819548 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Chrna4 |
cholinergic receptor, nicotinic, alpha polypeptide 4 |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein |
CTD |
PMID:23429044 |
|
NCBI chr 2:180,664,104...180,685,339
Ensembl chr 2:180,660,173...180,685,339
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of CHRNB2 protein |
CTD |
PMID:23429044 |
|
NCBI chr 3:89,660,755...89,671,939
Ensembl chr 3:89,653,502...89,671,939
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CXCL8 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cyp2a5 |
cytochrome P450, family 2, subfamily a, polypeptide 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2A6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2c52-ps |
cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Cyp7b1 |
cytochrome P450, family 7, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:18,126,108...18,298,054
Ensembl chr 3:18,126,114...18,297,502
|
|
G |
Cyp8b1 |
cytochrome P450, family 8, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:44,252,680...44,256,851
Ensembl chr12:44,252,342...44,257,109
|
|
G |
Dnajc10 |
DnaJ heat shock protein family (Hsp40) member C10 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:80,145,790...80,184,399
Ensembl chr 2:80,145,810...80,184,387
|
|
G |
Dnajc18 |
DnaJ heat shock protein family (Hsp40) member C18 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:35,804,156...35,841,467
Ensembl chr18:35,804,156...35,841,467
|
|
G |
Dnajc9 |
DnaJ heat shock protein family (Hsp40) member C9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:20,434,706...20,438,978
Ensembl chr14:20,434,706...20,438,978
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
increases activity multiple interactions |
ISO |
Tartrazine results in increased activity of ESR1 protein fulvestrant inhibits the reaction [Tartrazine results in increased activity of ESR1 protein] |
CTD |
PMID:22562034 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Fmo1 |
flavin containing monooxygenase 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179
|
|
G |
Fth1 |
ferritin heavy polypeptide 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:57,336,059...57,342,159
Ensembl chr14:57,336,057...57,342,159
|
|
G |
Gprc5b |
G protein-coupled receptor, family C, group 5, member B |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:118,571,263...118,594,434
Ensembl chr 7:118,571,270...118,594,434
|
|
G |
Grin2a |
glutamate receptor, ionotropic, NMDA2A (epsilon 1) |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of GRIN2A protein; [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of GRIN2A protein |
CTD |
PMID:23429044 |
|
NCBI chr16:9,385,765...9,813,744
Ensembl chr16:9,385,762...9,813,424
|
|
G |
Gsta3 |
glutathione S-transferase, alpha 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:21,310,837...21,335,885
Ensembl chr 1:21,310,813...21,335,885
|
|
G |
Gstt1 |
glutathione S-transferase, theta 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[Tartrazine co-treated with Erythrosine] affects the expression of HAVCR1 mRNA |
CTD |
PMID:32981412 |
|
NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405
|
|
G |
Hpx |
hemopexin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:105,240,818...105,249,323
Ensembl chr 7:105,240,820...105,249,344
|
|
G |
Ifi204 |
interferon activated gene 204 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI16 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:173,574,859...173,594,606
Ensembl chr 1:173,574,859...173,594,509
|
|
G |
Ifi27 |
interferon, alpha-inducible protein 27 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:103,400,448...103,406,504
Ensembl chr12:103,400,470...103,406,498
|
|
G |
Il1r1 |
interleukin 1 receptor, type I |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:40,261,651...40,355,361
Ensembl chr 1:40,264,240...40,356,417
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Lipc |
lipase, hepatic |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:16,758,680...16,779,829
Ensembl chr 1:16,758,275...16,779,835
|
|
G |
Maf |
MAF bZIP transcription factor |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:116,429,992...116,433,633
Ensembl chr 8:116,409,681...116,434,533
|
|
G |
Maff |
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:79,230,813...79,243,278
Ensembl chr15:79,230,821...79,243,276
|
|
G |
Map2k2 |
mitogen-activated protein kinase kinase 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:19,809,847...20,018,496
Ensembl chr10:19,810,218...20,018,499
|
|
G |
Mapkapk3 |
mitogen-activated protein kinase-activated protein kinase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:107,132,125...107,167,082
Ensembl chr 9:107,132,126...107,167,076
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:138,117,525...138,133,753
Ensembl chr 6:138,117,314...138,133,753
|
|
G |
Mlkl |
mixed lineage kinase domain-like |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:112,037,879...112,065,081
Ensembl chr 8:112,038,429...112,064,809
|
|
G |
Mmut |
methylmalonyl-Coenzyme A mutase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:41,245,576...41,272,880
Ensembl chr17:41,245,576...41,272,879
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Pah |
phenylalanine hydroxylase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:87,357,657...87,419,999
Ensembl chr10:87,357,657...87,419,998
|
|
G |
Pik3c2a |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:115,936,500...116,042,693
Ensembl chr 7:115,936,500...116,042,684
|
|
G |
Pik3c2g |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:139,591,070...139,915,010
Ensembl chr 6:139,564,219...139,915,010
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:116,078,593...116,160,253
Ensembl chr 4:116,078,815...116,160,253 Ensembl chr 4:116,078,815...116,160,253
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:36,709,131...36,714,004
Ensembl chr19:36,709,131...36,714,053
|
|
G |
Prkd3 |
protein kinase D3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:79,256,834...79,328,245
Ensembl chr17:79,256,834...79,328,245
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:98,818,626...98,865,768
Ensembl chr11:98,818,644...98,865,768
|
|
G |
Rasd1 |
RAS, dexamethasone-induced 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:59,854,007...59,855,770
Ensembl chr11:59,854,007...59,855,770
|
|
G |
Rdh16 |
retinol dehydrogenase 16 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:127,636,959...127,651,715
Ensembl chr10:127,637,021...127,682,434
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sorl1 |
sortilin-related receptor, LDLR class A repeats-containing |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:41,876,005...42,035,593
Ensembl chr 9:41,876,016...42,035,593
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:13,530,171...13,571,335
Ensembl chr 7:13,530,171...13,571,334
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [Tartrazine results in increased expression of TFF1 mRNA] |
CTD |
PMID:22562034 |
|
NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:45,848,702...45,864,112
Ensembl chr 8:45,848,702...45,864,117
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Tartrazine co-treated with Erythrosine] results in increased expression of TNF mRNA |
CTD |
PMID:32981412 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf9 |
tumor necrosis factor receptor superfamily, member 9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:151,004,612...151,030,561
Ensembl chr 4:150,999,019...151,030,559
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|